EUCTR2014-000554-10-ES进行中（未招募）1 期
A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hematopoietic stem cell transplant in patients with newly-diagnosed, symptomatic multiple myeloma.
Fundación PETHEMA0 个研究点目标入组 316 人开始时间: 2014年5月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 316
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The patient must, in the opinion of the investigator, be capable of complying with all requirements of the trial.
- •Have signed the informed consent form
- •Be between 18 and 67 years of age
- •Have an ECOG Performance Status ? 2 (or 3 if the ECOG is due to myeloma, e.g. pathological fracture)
- •Multiple myeloma patient who was included in the GEM2012MENOS65 trial, and who is found to have, at a minimum, minimal response after consolidation
- •Life expectancy > 3 months
- •The patient must have the following laboratory values in the 21 days prior to initiation of treatment (day 1, cycle 1):
- •Platelet count ? 100 x 109/L and absolute neutrophil count of ? 1.0 x 109/L. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment.
- •Corrected serum calcium < 14 mg/dL.
- •Aspartate transaminase (AST) and alanine transaminase (ALT) ? 2.5 x the upper limit of normal (ULN)
- •Total bilirubin within normal range
- •Calculated creatinine clearance > 30 mL/min
- •Female patients who:
- •Are postmenopausal for at least 1 year before the screening visit, OR
- •Are surgically sterile, OR
- •If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, AND
- •Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
- •Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- •Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:
- •Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR
- •Must also adhere to the guidelines of any treatment-specific pregnancy prevention program, if applicable, OR
- •Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 316
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Patients not included in clinical trial GEM2012MENOS65
- •Patients included in GEM2012MENOS65 who are not found to have a least minimal response after consolidation
- •Patients included in GEM2012MENOS65 who were discontinued prematurely due to toxicity or disease progression
- •Female patients who are lactating or have a positive serum pregnancy test during the screening period.
- •Central nervous system involvement
- •Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
- •Systemic treatment, within 14 days before the first dose of MLN9708, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John?s wort.
- •Any serious medical or psychiatric illness that could, in the investigator?s opinion, potentially interfere with the completion of treatment according to this protocol.
- •Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of MLN9708 including difficulty swallowing.
- •Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
- •Peripheral neuropathy ? grade 2 in the 21 days prior to inclusion.
- •Known hypersensitivity to lenalidomide or to MLN9708, their analogues, or excipients in the various formulations of any agent.
- •Patients who have had a myocardial infarction in the six months prior to inclusion in the clinical trial, or who are class III or IV according to the New York Heart Association (NYHA), heart failure unstable angina, uncontrolled ventricular arrhythmias or acute ischemia detected by electrocardiogram, or conduction disorders.
- •Patients who are currently participating in another clinical trial or receiving any other investigational product.
- •Seropositive for HVB, HVC or HIV.
研究者
相似试验
招募中
不适用
A prospective, randomized, open-label, multicenter, parallel design, phase III study to assess the efficacy and safety of GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in treating locally advanced and metastatic pancreatic cancer patientsNeoplasmsKCT0002159Samsung Pharmaceutical148
进行中（未招募）
1 期
A multicenter, open-label, Prospective, randomized parallel group Phase III study investigating the benefit on Renal function of a CNI-free regimen with MyfOrtic® (mycophenolate sodium) and Certican® (everolimus) in coMparison to therapy with CErTican® (everolimus) and Prograf® (tacrolimus) in de novo rEnal transplant patients at 12 months post transplantatioKidney transplantationEUCTR2013-001798-26-FRCHU DE POITIERS390
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 20.0 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-SKAB Science80
进行中（未招募）
不适用
Evaluation of masitinib in patients with advanced ovarian cancerAdvanced / metastatic epithelial ovarian cancer patients in secondline being refractory to first line platinum treatment or in third lineMedDRA version: 18.0Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-GBAB Science80
进行中（未招募）
不适用
Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 16.1Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000491-14-FRAB Science56